Pneumocandins from Zalerion arboricola. I. Discovery and isolation.
HPLC bioautography of the directed biosynthesis of Zalerion arboricola led to the discovery of pneumocandin B0 (L-688,786), a new antifungal and anti-Pneumocystis carinii lipopeptide. Isolation techniques were developed to separate this component from pneumocandin A0 (L-671,329) in fermentations of a mutant of Zalerion arboricola. A number of related compounds were also isolated, which differ from pneumocandins A0 and B0 in the hydroxylation patterns on the ornithine, homotyrosine, and proline.
Schwartz
R E
RE
Merck Research Laboratories, Rahway, N.J. 07065-0900.
Sesin
D F
DF
Joshua
H
H
Wilson
K E
KE
Kempf
A J
AJ
Goklen
K A
KA
Kuehner
D
D
Gailliot
P
P
Gleason
C
C
White
R
R
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D001711:Biotransformation; D002176:Candida albicans / Q000187:drug effects; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D054714:Echinocandins; D008826:Microbial Sensitivity Tests; D008828:Microbiological Techniques; D003904:Mitosporic Fungi / Q000737:chemistry* / Q000378:metabolism; D010455:Peptides; D010456:Peptides, Cyclic / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D011010:Pneumocystis / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D010455:Peptides; D010456:Peptides, Cyclic; C058995:pneumocandin A(0); C079465:pneumocandin B(0); C079464:pneumocandin C(0)